March 30, 2018 / 5:40 AM / 25 days ago

BRIEF-Neovacs FY Net Loss at EUR 14.8 Mln, Expects to Report Results Of Phase IIB Clinical Trial In Lupus In Mid-2018

March 30 (Reuters) - Neovacs Sa:

* FY OPERATING LOSS EUR ‍​18.3 MILLION VERSUS LOSS OF EUR 17.3 MILLION YEAR AGO

* FY REVENUE EUR ‍​0.8 MILLION VERSUS EUR 0.4 MILLION YEAR AGO

* FY NET LOSS EUR ‍​14.8 MILLION VERSUS LOSS OF EUR 13.9 MILLION YEAR AGO

* BASED ON POSITIVE OUTCOME OF IFN-ALPHA KINOID LUPUS STUDY, INTENDS TO FILE FOR ORPHAN DRUG DESIGNATION IN SOUTH KOREA WITH CKD IN 2018

* ELIGIBLE TO RECEIVE MILESTONE PAYMENTS IN H2 FROM 3 INTERNATIONAL PARTNERS, PENDING POSITIVE RESULTS OF IFN-ΑLPHA KINOID PHASE IIB CLINICAL TRIAL IN LUPUS

* NEOSTELL PROJECT EXPECTED TO START IN H2 2018 AND BE COMPLETED IN 2023

* AT DEC. 31, 2017, NEOVACS HAD CASH AND CASH EQUIVALENTS OF EUR 5.1 MILLION

* EXPECTS TO REPORT RESULTS OF PHASE IIB CLINICAL TRIAL IN LUPUS IN MID-2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below